Long Term Use of Somatropin in Patients Small for Gestational Age

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00793325
First received: November 17, 2008
Last updated: December 17, 2013
Last verified: December 2013

November 17, 2008
December 17, 2013
February 2009
December 2012   (final data collection date for primary outcome measure)
  • Number of Participants With Treatment Related Adverse Events. [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    Adverse events mean all unfavorable events that occur in participants after administration of somatropin, irrespective of causal relationship to somatropin (including clinically problematic abnormal changes in laboratory test values). Treatment related adverse events were evaluated in company with the causal relationship to somatropin.
  • Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert. [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    Adverse events mean all unfavorable events that occur in participants after administration of somatropin, irrespective of causal relationship to somatropin (including clinically problematic abnormal changes in laboratory test values). Treatment related adverse events were evaluated in company with the causal relationship to somatropin. Unlisted treatment related adverse events were confirmed with listed adverse drug reaction according to Japanese package insert.
  • Number of Participants With Treatment Related Adverse Events of Somatropin: <15 Years of Age vs. >=15 Years of Age. [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    To determine whether age is a significant risk factor in the frequency of treatment related adverse events.
  • Number of Participants With Treatment Related Adverse Events of Somatropin by Gender. [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    To determine whether gender is a significant risk factor in the frequency of treatment related adverse events.
  • Number of Participants With Treatment Related Adverse Events of Somatropin Based on SGA Severity. [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    To determine whether severity of SGA is a significant risk factor in the frequency of treatment related adverse events. The severity of SGA was comprehensively evaluated on the basis of information including height and weight at birth and height measured one year before the start of administration.
  • Number of Participants With Treatment Related Adverse Events of Somatropin: With Past History of Any Disease vs. Without Past History of Any Disease. [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    To determine whether past history of any disease is a significant risk factor in the frequency of treatment related adverse events.
  • Number of Participants With Treatment Related Adverse Events of Somatropin: With Complications vs. Without Complications [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    To determine whether having complication(s) is a significant risk factor in the frequency of treatment related adverse events.
  • Number of Participants With Treatment Related Adverse Events of Somatropin: With Hepatic Function Disorder vs. Without Hepatic Function Disorder. [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    To determine whether hepatic function disorder is a significant risk factor in the frequency of treatment related adverse events.
  • Number of Participants With Treatment Related Adverse Events of Somatropin: With Renal Impairment vs. Without Renal Impairment. [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    To determine whether renal impairment is a significant risk factor in the frequency of treatment related adverse events.
  • Number of Participants With Treatment Related Adverse Events of Somatropin: With Concomitant Drug(s) vs. Without Concomitant Drug(s). [ Time Frame: Up to 3 years ] [ Designated as safety issue: Yes ]
    To determine whether taking concomitant drug(s) is a significant risk factor in the frequency of treatment related adverse events.
  • Change in the Growth Rate Standard Deviation (SD) Score for Calendar Age. [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    Growth rate SD score = (Growth rate - Average growth rate for calendar age of gender) / SD score for growth rate for each calendar age of gender). An SD score indicates how far a participant's score deviates from the mean of the reference population; an SD score higher than the mean gives a positive SD score whereas an SD score lower than the mean gives a negative SD score. In addition, when the bone age was described, it was to be read as the calendar age for men who were 11 years or older and women who were 9 years or older, as necessary.
  • Change in Height SD Score for Calendar Age. [ Time Frame: Up to 3 years ] [ Designated as safety issue: No ]
    The change in height standard SD for calendar age = (Height SD score for each calendar age - Height SD score for calendar age of the previous year) / (the date on which the height was measured - the date of the previous year on which the height was measured) × 365.25.
  • Factors considered to affect the safety and/or efficacy of this drug. [ Time Frame: 3 years maximum ] [ Designated as safety issue: No ]
  • The incidence of adverse drug reactions in this surveillance. [ Time Frame: 3 years maximum ] [ Designated as safety issue: No ]
  • Adverse drug reaction not expected from the LPD (unknown adverse drug reaction). [ Time Frame: 3 years maximum ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00793325 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Long Term Use of Somatropin in Patients Small for Gestational Age
Special Investigation Of Long Term Use Of Genotropin For SGA (Regulatory Post Marketing Commitment Plan)

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

All the patients whom an investigator prescribes the first Genotropin® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

The patients whom an investigator involving A6281292 prescribes the Somatropin (Genotropin® ).

Small for Gestational Age
Drug: Somatropin

Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.

Frequency and duration are according to Package Insert as follows. " Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."

Other Name: Genotropin
Somatropin
Patients administered Somatropin.
Intervention: Drug: Somatropin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
920
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients need to be administered Somatropin (Genotropin®) in order to be enrolled in the surveillance.

Exclusion Criteria:

  • Patients not administered Somatropin (Genotropin®).
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00793325
A6281292
No
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP